logo
Plus   Neg
Share
Email

Amgen: GALACTIC-HF Trial Meets Primary Composite Endpoint; Fails To Meet Secondary Endpoint

Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier announced topline results from GALACTIC-HF, a phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction. The company said the results of GALACTIC-HF showed that treatment with omecamtiv mecarbil achieved the primary composite efficacy endpoint and demonstrated a statistically significant effect to reduce cardiovascular death or heart failure events compared to placebo. No reduction in the secondary endpoint of cardiovascular death was observed in the trial.

The results from GALACTIC-HF will be presented at the American Heart Association Scientific Sessions 2020, in a virtual Late Breaking Clinical Trial session on November 13.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Union and Britain have cleared Boeing's 737 Max for return to service in their respective regions after being grounded for nearly two years. The EU's air safety watchdog European Union Aviation Safety Agency or EASA in a statement said the agency has approved the return to service of a modified version of the Boeing 737 MAX. The UK Civil Aviation Authority or CAA also lifted the ban. Euromarket Designs, Inc., doing business as CB2, has recalled Junction tall chests and low dressers citing tip-over and entrapment hazards to children, according to the U.S. Consumer Product Safety Commission. The Chicago, Illinois - based company has called back about 11,000 units sold in the United States and about 355 units sold in Canada. Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) reported a profit for the fourth-quarter that increased 23.3 percent from last year, led by display and memory chip businesses.Quarterly revenue grew 2.8 percent from the prior year. The company expects overall profit to weaken in the first quarter of 2021.
Follow RTT